So far, three cases of monkey pox have been confirmed in Sweden. The first case concerns a person in the Stockholm Region and in the second case – which was reported on Wednesday – it concerns a person in the Västra Götaland region. On Monday, the Swedish Public Health Agency stated that another person in the Stockholm Region had been confirmed infected.

The government is now announcing that Sweden will participate in a planned procurement of Imvanex – a vaccine that was initially developed against smallpox, but also protects against monkey smallpox. The vaccine is approved within the EU.

There are also plans to participate in a planned procurement of the antiviral drug Tecovirimat, which can be used against smallpox.

The Swedish Public Health Agency and the National Board of Health and Welfare are now reviewing which volumes of vaccines and medicines may be relevant for Sweden.

– EU-joint purchases of vaccines and medicines served us well during the pandemic and can now do it again, says Minister of Social Affairs Lena Hallengren (S), in a press release.

Since 20 May, monkey pox has been classified as a general dangerous disease, which means that infection control measures such as infection tracing and rules of conduct can be used to limit the spread. By May 25, a total of 118 cases of monkey pox had been confirmed in the EU, according to the European Agency for Communicable Disease Control (ECDC).